Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Roschewski Website

Mark J. Roschewski, M.D.

Selected Publications

1)  Roschewski M, Staudt LM, Wilson WH.
Diffuse large B-cell lymphoma-treatment approaches in the molecular era.
Nat Rev Clin Oncol. 11: 12-23, 2014.
2)  Roschewski M, Dunleavy K, Wilson WH.
Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma.
Leuk. Lymphoma. [Epub ahead of print], 2014.
3)  Roschewski M, Korde N, Wu SP, Landgren O.
Pursuing the curative blueprint for early myeloma.
Blood. 122: 486-90, 2013.
4)  Roschewski M, Stetler-Stevenson M, Yuan C, Mailankody S, Korde N, Landgren O.
Minimal residual disease: what are the minimum requirements?.
J. Clin. Oncol. 32: 475-6, 2014.
5)  Roschewski M, Wilson WH.
EBV-associated lymphomas in adults.
Best Pract Res Clin Haematol. 25: 75-89, 2012.
6)  Korde N, Carlsten M, Lee M, Minter A, Tan E, Kwok M, Manasanch E, Bhutani M, Tageja N, Roschewski M, Zingone A, Costello R, Mulquin M, Zuchlinski D, Maric I, Calvo KR, Braylan R, Tembhare P, Yuan C, Stetler-Stevenson M, Trepel J, Childs R, Landgren O.
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.
Haematologica. 99: e81-3, 2014.
7)  Tembhare PR, Yuan CM, Venzon D, Braylan R, Korde N, Manasanch E, Zuchlinsky D, Calvo K, Kurlander R, Bhutani M, Tageja N, Maric I, Mulquin M, Roschewski M, Kwok M, Liewehr D, Landgren O, Stetler-Stevenson M.
Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases.
Leuk. Res. 38: 371-6, 2014.
8)  Roschewski M, Manasanch EE, Wilson WH.
Management of heavy chain diseases: the challenges of biologic heterogeneity.
Oncology (Williston Park, N.Y.). 28: 63-5, 2014.
9)  Landgren O, Graubard BI, Katzmann JA, Kyle RA, Ahmadizadeh I, Clark R, Kumar SK, Dispenzieri A, Greenberg AJ, Therneau TM, Melton LJ, Caporaso N, Korde N, Roschewski M, Costello R, McQuillan GM, Rajkumar SV.
Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12?482 persons from the National Health and Nutritional Examination Survey.
Leukemia. 28: 1537-42, 2014.
10)  Tageja N, Manasanch EE, Korde N, Kwok M, Mailankody S, Bhutani M, Roschewski M, Landgren O.
Smoldering multiple myeloma: present position and potential promises.
Eur. J. Haematol. 92: 1-12, 2014.
11)  Manasanch EE, Korde N, Zingone A, Tageja N, Fernandez de Larrea C, Bhutani M, Wu P, Roschewski M, Landgren O.
The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma.
Leuk. Lymphoma. [Epub ahead of print], 2014.
12)  Davidson-Moncada JK, McDuffee E, Roschewski M.
CD5+ diffuse large B-cell lymphoma with hemophagocytosis.
J. Clin. Oncol. 31: e76-9, 2013.
13)  Cherry BM, Korde N, Kwok M, Roschewski M, Landgren O.
Evolving therapeutic paradigms for multiple myeloma: back to the future.
Leuk. Lymphoma. 54: 451-63, 2013.
14)  Cherry BM, Costello R, Zingone A, Burris J, Korde N, Manasanch E, Kwok M, Annunziata C, Roschewski MJ, Engels EA, Landgren O.
Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age.
Am. J. Hematol. 88: 89-92, 2013.
15)  Manasanch EE, Braylan R, Stetler-Stevenson M, Yuan C, Gounden V, Korde N, Tageja N, Bhutani M, Calvo K, Maric I, Roschewski M, Staudt LM, Landgren O.
Lack of MYD88 L265P in non-immunoglobulin M lymphoplasmacytic lymphoma.
Leuk. Lymphoma. 2013.
16)  Cherry BM, Korde N, Kwok M, Manasanch EE, Bhutani M, Mulquin M, Zuchlinski D, Yancey MA, Maric I, Calvo KR, Braylan R, Stetler-Stevenson M, Yuan C, Tembhare P, Zingone A, Costello R, Roschewski MJ, Landgren O.
Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study.
Leuk. Lymphoma. [Epub ahead of print], 2013.
17)  Roschewski M, Farooqui M, Aue G, Wilhelm F, Wiestner A.
Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies.
Leukemia. 27: 1920-3, 2013.
18)  Roschewski M, Dunleavy K, Wilson WH.
Diffuse large B cell lymphoma: molecular targeted therapy.
Int. J. Hematol. 96: 552-61, 2012.
19)  Gilstad C, Roschewski M, Wells J, Delmas A, Lackey J, Uribe P, Popa C, Jardeleza T, Roop S.
Fatal transfusion-associated graft-versus-host disease with concomitant immune hemolysis in a group A combat trauma patient resuscitated with group O fresh whole blood.
Transfusion. 52: 930-5, 2012.
20)  Roschewski M, Wilson WH.
Lymphomatoid granulomatosis.
Cancer J. 18: 469-74, 2012.
21)  Dunleavy K, Roschewski M, Wilson WH.
Lymphomatoid granulomatosis and other Epstein-Barr virus associated lymphoproliferative processes.
Curr Hematol Malig Rep. 7: 208-15, 2012.
22)  Lai C, Roschewski M.
Nodal marginal zone lymphoma: impersonalized medicine.
Oncology (Williston Park, N.Y.). 26: 104, 106, 108, 2012.
23)  Chapman CM, Sun X, Roschewski M, Aue G, Farooqui M, Stennett L, Gibellini F, Arthur D, Pérez-Galán P, Wiestner A.
ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress.
Clin. Cancer Res. 18: 1979-91, 2012.
24)  Roschewski M, Wilson WH.
Biology and management of rare primary extranodal T-cell lymphomas.
Oncology (Williston Park, N.Y.). 24: 94-100, 2010.
25)  Brown G, Shapeero LG, Weiss BM, Roschewski M.
Multiple myeloma with lacrimal gland amyloidosis and sarcoidosis.
Am. J. Hematol. 85: 506-9, 2010.
Click Here to View Collapsed Bibliography.

This page was last updated on 7/14/2014.